Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CLRB
stocks logo

CLRB

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.220
+306.67%
--
--
-2.023
-51.83%
--
--
-1.987
-41.4%
Estimates Revision
The market is revising No Change the revenue expectations for Cellectar Biosciences, Inc. (CLRB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -23.69%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-26.37%
In Past 3 Month
Stock Price
Go Down
down Image
-23.69%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Cellectar Biosciences Inc (CLRB.O) is -0.52, compared to its 5-year average forward P/E of -1.50. For a more detailed relative valuation and DCF analysis to assess Cellectar Biosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.50
Current PE
-0.52
Overvalued PE
-0.44
Undervalued PE
-2.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.26
Current PS
0.00
Overvalued PS
6.30
Undervalued PS
-3.79
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 1385.12% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 1385.12% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

CLRB News & Events

Events Timeline

(ET)
2025-11-13
07:22:44
Cellectar Biosciences Announces Q3 EPS of $1.41, Below Consensus Estimate of $2.53
select
2025-10-27 (ET)
2025-10-27
08:37:01
Cellectar Biosciences Granted RPDD by U.S. FDA for Iopofosine I 131
select
2025-10-14 (ET)
2025-10-14
08:33:01
Cellectar Biosciences Showcases Posters on CLR 121225 and CLR 225 at AACR
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
11-13SeekingAlpha
Cellectar Indicates 2027 Worldwide Release for Iopofosine as Regulatory Progress Gains Speed

  • Management Progress: Cellectar Biosciences reported significant advancements in Q3 2025, including eligibility for conditional marketing approval in the EU for iopofosine, with plans for a potential global launch by 2027. The company is also advancing clinical programs for CLR 125 and CLR 225.

  • Financial Overview: The company ended the quarter with $12.6 million in cash, down from $23.3 million at the end of 2024, but raised $5.8 million through stock issuance. Research and development expenses decreased significantly, contributing to a net loss of $4.4 million for the quarter.

  • Regulatory and Strategic Outlook: Management is optimistic about regulatory progress and is in discussions with potential partners for iopofosine. They plan to submit the application for EU marketing approval in mid-2026, with U.S. approval potentially occurring sooner.

  • Risks and Challenges: Financing remains a critical challenge for advancing clinical trials, particularly for the Phase III study in the U.S. Additionally, pricing negotiations in Europe may impact revenue potential, highlighting the need for sufficient funding to support ongoing operations and regulatory filings.

[object Object]
Preview
9.5
11-13Newsfilter
Cellectar Biosciences Announces Financial Results for Q3 2025 and Shares Corporate Developments

  • Regulatory Progress: Cellectar Biosciences plans to submit a Conditional Marketing Approval application for iopofosine I 131 in Europe for Waldenstrom's Macroglobulinemia in 2026, following positive feedback from the European Medicines Agency.

  • Clinical Trials Initiated: The company has initiated a Phase 1b study for CLR 125 targeting triple-negative breast cancer and received Rare Pediatric Drug Designation for iopofosine I 131 in pediatric high-grade glioma.

  • Financial Overview: Cellectar reported a net loss of $4.4 million for Q3 2025, a significant decrease from $14.7 million in the same period the previous year, and raised approximately $12.7 million to support ongoing studies.

  • Upcoming Conference Call: Cellectar management will host a conference call and webcast on November 13, 2025, to discuss financial results and corporate updates, accessible via their website.

[object Object]
Preview
8.5
10-07Newsfilter
Cellectar Biosciences, Inc. Secures $5.8 Million Through New Agreements

  • Funding Announcement: Cellectar Biosciences has entered an agreement with institutional investors to exercise existing warrants, generating approximately $5.8 million in gross proceeds for the company.

  • Use of Proceeds: The funds will be allocated for working capital, a Phase 1b clinical study of CLR 121125 in triple-negative breast cancer, and preparations for a Conditional Marketing Authorization with the European Medicines Agency.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Cellectar Biosciences Inc (CLRB) stock price today?

The current price of CLRB is 3.8 USD — it has increased 2.98 % in the last trading day.

arrow icon

What is Cellectar Biosciences Inc (CLRB)'s business?

Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.

arrow icon

What is the price predicton of CLRB Stock?

Wall Street analysts forecast CLRB stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLRB is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Cellectar Biosciences Inc (CLRB)'s revenue for the last quarter?

Cellectar Biosciences Inc revenue for the last quarter amounts to -4.85M USD, decreased -63.60 % YoY.

arrow icon

What is Cellectar Biosciences Inc (CLRB)'s earnings per share (EPS) for the last quarter?

Cellectar Biosciences Inc. EPS for the last quarter amounts to -4275121.00 USD, decreased -53.36 % YoY.

arrow icon

What changes have occurred in the market's expectations for Cellectar Biosciences Inc (CLRB)'s fundamentals?

The market is revising No Change the revenue expectations for Cellectar Biosciences, Inc. (CLRB) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -23.69%.
arrow icon

How many employees does Cellectar Biosciences Inc (CLRB). have?

Cellectar Biosciences Inc (CLRB) has 11 emplpoyees as of December 05 2025.

arrow icon

What is Cellectar Biosciences Inc (CLRB) market cap?

Today CLRB has the market capitalization of 16.02M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free